Conjugated C-6 hydroxylated bile acids in serum relate to human metabolic health and gut Clostridia species Show others and affiliations
2021 (English) In: Scientific Reports, E-ISSN 2045-2322, Vol. 11, no 1, article id 13252Article in journal (Refereed) Published
Abstract [en]
Knowledge about in vivo effects of human circulating C-6 hydroxylated bile acids (BAs), also called muricholic acids, is sparse. It is unsettled if the gut microbiome might contribute to their biosynthesis. Here, we measured a range of serum BAs and related them to markers of human metabolic health and the gut microbiome. We examined 283 non-obese and obese Danish adults from the MetaHit study. Fasting concentrations of serum BAs were quantified using ultra-performance liquid chromatography-tandem mass-spectrometry. The gut microbiome was characterized with shotgun metagenomic sequencing and genome-scale metabolic modeling. We find that tauro- and glycohyocholic acid correlated inversely with body mass index (P = 4.1e-03, P = 1.9e-05, respectively), waist circumference (P = 0.017, P = 1.1e-04, respectively), body fat percentage (P = 2.5e-03, P = 2.3e-06, respectively), insulin resistance (P = 0.051, P = 4.6e-4, respectively), fasting concentrations of triglycerides (P = 0.06, P = 9.2e-4, respectively) and leptin (P = 0.067, P = 9.2e-4). Tauro- and glycohyocholic acids, and tauro-a-muricholic acid were directly linked with a distinct gut microbial community primarily composed of Clostridia species (P = 0.037, P = 0.013, P = 0.027, respectively). We conclude that serum conjugated C-6-hydroxylated BAs associate with measures of human metabolic health and gut communities of Clostridia species. The findings merit preclinical interventions and human feasibility studies to explore the therapeutic potential of these BAs in obesity and type 2 diabetes.
Place, publisher, year, edition, pages Nature Publishing Group, 2021. Vol. 11, no 1, article id 13252
National Category
Endocrinology and Diabetes
Identifiers URN: urn:nbn:se:oru:diva-92680 DOI: 10.1038/s41598-021-91482-y ISI: 000670729700029 PubMedID: 34168163 Scopus ID: 2-s2.0-85108620208 OAI: oai:DiVA.org:oru-92680 DiVA, id: diva2:1573909
Funder Novo Nordisk Academy of Finland, 333981
Note Funding Agency:
Metagenopolis grant ANR-11-DPBS-0001
2021-06-282021-06-282022-09-15 Bibliographically approved